More than just optimizing treatment efficacy, orally disintegrating tablets (ODT) - an advanced dosage form that dissolves quickly, is easy to use, and suitable for all ages - are being advanced by Imexpharm as a convenient and effective healthcare solution for the community.
ODT: A leap forward in modern pharmaceutical technology
In recent years, the medical field in general and Imexpharm in particular has been continuously researching and developing advanced drug formulation technologies to optimize therapeutic outcomes and enhance the patient experience. Beyond determining the speed of absorption and bioavailability of active ingredients, innovative dosage forms also improve ease of use, especially for pediatric and elderly patients.
In Vietnam, Imexpharm is among the pioneers of this trend, with a portfolio featuring modern dosage technologies such as ODT. These tablets dissolve rapidly in the mouth, are easy to swallow, simple to split into doses, and offer a treatment option that is more convenient, user-friendly, and easier for patients to follow.
Mechanism and benefits of ODT
According to the European Pharmacopoeia, ODTs are solid tablets that dissolve or disperse in the mouth within no more than three minutes. When in contact with saliva, water penetrates through microcapillaries, causing excipients to swell and break the tablet into tiny particles, releasing the active ingredient quickly. This allows the drug to be absorbed earlier, reducing onset time compared to conventional tablets.
In addition to pharmacological benefits, ODTs enable flexible dose adjustments, improve palatability with mild flavors, and increase adherence which is a critical factor in long-term treatments. As a result, ODTs are not only a technological advancement but also a reflection of patient-centric care in every tablet.
ODT and Imexpharm’s long-term investment strategy
Driven by the belief that every patient deserves the right treatment, Imexpharm consistently follows its R&D strategy, focusing on expanding advanced dosage forms and high-technology pharmaceuticals such as first generics and biosimilars.
The R&D team actively explores innovative dosage forms including lyophilization, ODT, and multi-dose powders - all developed using cutting-edge technologies and subject to strict impurity control in compliance with international standards.
Alongside high-tech manufacturing facilities and rigorous production processes, Imexpharm sources raw materials exclusively from trusted suppliers to ensure patient safety.
Currently, Imexpharm operates three EU-GMP factory clusters and 12 EU-GMP production lines, with a steady increase in in-depth R&D investment averaging around 6% annual growth in spending and maintains roughly 100 ongoing research projects. Beyond its internal capabilities, in early 2024, Imexpharm partnered with Genuone Sciences Inc., a leading Korean pharmaceutical group, to promote advanced technology transfer. This enables the company to independently produce and manage high-quality specialty drugs at reasonable costs, helping to reduce the financial burden on patients, especially in the context of emerging public health challenges.
In parallel, to contribute to the development of domestic pharmaceutical infrastructure, particularly the growing wave of pharmaceutical industrial parks nationwide, Imexpharm is building the Cat Khanh Pharmaceutical Complex in Dong Thap Province on a 9.7-hectare site. Upon completion and full operation (with phased actual capacity), the facility is expected to have a designed capacity of up to 1.4 billion product units per year. It will serve as a hub for high-value, high-tech pharmaceuticals such as first generics, biosimilars, and complex dosage forms, including ODTs.
In 2025, the company targets revenue of VND 2,981 billion and pre-tax profit of VND 493.5 billion, representing year-on-year growth of 18.6% and 22.1% respectively. Advanced manufacturing technology and a lean management system form the foundation for accelerating product innovation and expanding access to effective treatments. The launch of 24 new products in 2024, half of which are injectables manufactured on EU-GMP lines, along with the distinction of being the only company in Vietnam to own an EU-GMP-certified Betalactam antibiotic plant for both injectable and oral forms, all point to one core mission: helping patients access better, more effective medicines at reasonable costs. Through comprehensive investment in both production technology and operational management, Imexpharm is steadily shortening the journey from laboratory to patient, delivering safe, effective, and timely treatment solutions to the community in a sustainable way.